Fenghuang “Frank” Zhan invested in inaugural Bart Barlogie Chair for Myeloma Research

OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma

A University of Oklahoma physician-researcher recently received $2.9 million in funding from NCI to study whether RedHill Biopharma’s drug opaganib, given after CAR T-cell therapy, can help the immune cells fight cancer more effectively.

October 23, 2026

Vol.52 No.39

Funding Opportunities

International Myeloma Society opens applications for over $3M in 2027 research funding

The International Myeloma Society, in partnership with the Paula and Rodger Riney Foundation, is accepting applications for more than $3 million in research funding through its 2027 Translational Research and Career Development awards. The awards support research to improve the prevention, early detection, diagnosis, and treatment of multiple myeloma and related plasma cell disorders, while developing the next generation of researchers in the field.

October 23, 2026

Vol.52 No.39

Clinical Roundup

Novel CAR T therapy for r/r MM shows deep and durable responses, phase I study finds

An investigational CAR T therapy can lead to deep and durable responses in people with relapsed/refractory multiple myeloma, according to a phase I clinical trial led by investigators at Mass General Brigham Cancer Institute and the University of Chicago Medicine Comprehensive Cancer Center.

October 23, 2026

Vol.52 No.39

Drugs & Targets

FDA grants accelerated approval to iberdomide combination for MM

FDA granted accelerated approval to iberdomide (Zenbexus) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

September 11, 2026

Vol.52 No.33

Drugs & Targets

FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma

August 14, 2026

Vol.52 No.32

Clinical Roundup

Lenalidomide maintenance may end after two years for patients with MM, phase III trial finds

For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard of care, despite limited evidence to guide the optimal duration of treatment.

July 17, 2026

Vol.52 No.28

Fenghuang “Frank” Zhan invested in inaugural Bart Barlogie Chair for Myeloma Research

YOU MAY BE INTERESTED IN

OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma

International Myeloma Society opens applications for over $3M in 2027 research funding

Novel CAR T therapy for r/r MM shows deep and durable responses, phase I study finds

FDA grants accelerated approval to iberdomide combination for MM

FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma

Lenalidomide maintenance may end after two years for patients with MM, phase III trial finds

Renew today!

Subscriber content

Never miss an issue!

Login